Home › Funds › SILVERARC CAPITAL MANAGEMENT, LLC › OVID
SILVERARC CAPITAL MANAGEMENT, LLC position in OVID
OVID THERAPEUTICS INC · Health Care
SILVERARC CAPITAL MANAGEMENT, LLC reported holding 5,950,000 shares of OVID (OVID THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$14.8M, representing 1.89% of its reported portfolio and ranking #15 among its reported holdings. SILVERARC CAPITAL MANAGEMENT, LLC has disclosed OVID holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How SILVERARC CAPITAL MANAGEMENT, LLC's OVID position evolved
SILVERARC CAPITAL MANAGEMENT, LLC first disclosed a stake in OVID in Q1 2026 at 1,000,000 shares (US$2.2M). The position peaked in Q3 2026 at 5,950,000 shares, worth US$14.8M. Across 3 filings, SILVERARC CAPITAL MANAGEMENT, LLC increased the stake 2 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 5,950,000 shares valued at US$14.8M — an increase of 2,848,871 shares quarter over quarter.. Notable position changes include a 210% increase in Q2 2026 (shares fell 7% over the following quarter), a 92% increase in Q3 2026 (shares rose 2% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 1.00M | $2.22M | New |
| Q2 2026 | 3.10M | $8.34M | Add |
| Q3 2026 | 5.95M | $14.82M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About OVID and 13F data
OVID (OVID THERAPEUTICS INC) is a Health Care company. 51 other funds we track also report a position in OVID — the largest reported positions include Affinity Asset Advisors, LLC (US$27.3M), ADAR1 Capital Management, LLC (US$20.0M), STEMPOINT CAPITAL LP (US$6.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding OVID
- Affinity Asset Advisors, LLC 10.14M sh · $27.29M · Q2 2026
- ADAR1 Capital Management, LLC 7.42M sh · $19.95M · Q2 2026
- STEMPOINT CAPITAL LP 2.42M sh · $6.50M · Q2 2026
- Ikarian Capital, LLC 2.27M sh · $6.11M · Q2 2026
- Rosalind Advisors, Inc. 1.11M sh · $2.98M · Q2 2026
- Sio Capital Management, LLC 1.01M sh · $2.70M · Q2 2026
- Propel Bio Management, LLC 1.02M sh · $2.54M · Q3 2026
- Saturn V Capital Management LP 663.06K sh · $1.78M · Q2 2026
- Ally Bridge Group (NY) LLC 624.56K sh · $1.68M · Q2 2026
More on SILVERARC CAPITAL MANAGEMENT, LLC
FAQ
How long has SILVERARC CAPITAL MANAGEMENT, LLC held OVID?
SILVERARC CAPITAL MANAGEMENT, LLC has disclosed OVID holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
What is SILVERARC CAPITAL MANAGEMENT, LLC's current position in OVID?
As of Q3 2026, SILVERARC CAPITAL MANAGEMENT, LLC holds 5.95M shares of OVID (OVID THERAPEUTICS INC), valued at $14.82M, representing 1.89% of its reported portfolio and ranking #15.
Has SILVERARC CAPITAL MANAGEMENT, LLC been buying or selling OVID?
In the latest 13F filing (Q3 2026), SILVERARC CAPITAL MANAGEMENT, LLC increased its position in OVID. The position peaked in Q3 2026 at 5.95M shares.
Which other funds hold OVID?
Other major institutional holders of OVID include Affinity Asset Advisors, LLC, ADAR1 Capital Management, LLC, STEMPOINT CAPITAL LP, among 51 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.